InvestorsHub Logo
Followers 468
Posts 26926
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 79

Friday, 09/28/2012 8:53:19 AM

Friday, September 28, 2012 8:53:19 AM

Post# of 132
TPI Reports Fiscal Year 2012 Financial Results
PR NewswirePress Release: Tianyin Pharmaceutical Co., Inc.

CHENGDU, China, Sept. 28, 2012 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012.

Fiscal Year 2012 Ended June 30, 2012 Financial Highlights:

FY2012 revenue delivered $69.6 million compared with $95.2 million in FY2011,
Operating income delivered $8.5 million, compared with $18.1 million in FY2011,
Net Income was $6.4 million compared with $15.7 million in FY2011,
Earnings per share of $0.22 per basic share, and $0.22 per diluted share, compared with $0.55 per basic share, or $0.53 per diluted share in FY2011,
Cash and cash equivalents totaled $35.2 million on June 30, 2012; Operating cash flow for the fiscal year ended June 30, 2012 was $8.0 million, compared with $14.2 million for the fiscal year ended June 30, 2011.

Comparison of results for the fiscal years ended June 30, 2012 and 2011:

* Net income includes a $1.6 million non-cash gain due to the change in the fair value of our warrants liability.

Sales for the fiscal year ended June 30, 2012 was $69.6 million, decreased 26.9% from $95.2 million for the fiscal year ended June 30, 2011, due to generic pricing pressure under the ongoing healthcare reform. We witnessed a 17% reduction of TPI's organic portfolio revenue from $63.9 million for the fiscal year 2011 to $53.0 million for the fiscal year 2012. Our core five products by sales are: Ginkgo Mihuan Oral Liquid (GMOL): $17.1 million; Apu Shuangxin Granules (APU) $2.7 million; Xuelian Chongcao (XLCC): $2.2 million; Azithromycin Dispersible Tablets (AZI): $3.0 million; Qingre Jiedu Oral Liquid (QRE): $3.5 million. The core product portfolio totaled $28.5 million or 53.8% of the organic portfolio revenue.

http://finance.yahoo.com/news/tpi-reports-fiscal-2012-financial-093600981.html